Log In
BCIQ
Print this Print this
 

Aducanumab (BIIB037)

  Manage Alerts
Collapse Summary General Information
Company Neurimmune Holding AG
DescriptionHuman recombinant anti-beta amyloid mAb
Molecular Target Beta amyloid
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationAlzheimer's disease (AD)
Indication DetailsTreat Alzheimer's disease (AD)
Regulatory Designation EU - PRIority MEdicines (PRIME) (Treat Alzheimer's disease (AD))
PartnerBiogen Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/10/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today